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Previous studies on human T lymphocytes have shown that the
degranulation marker CD107a can be used to deﬁne T cells, which
show tumor speciﬁc cytolysis. To determine whether CD107a can
be used in the murine setting as a marker for cytolysis, we ﬁrst
tested the degranulation activity on splenocytes from C57BL/6
(H-2b), FVB (H-2q) or Balb/c (H-2d) against Balb/c splenocytes.
Results from the mixed lymphocyte cytolytic assays (MLCA) and
cytolytic assays [51Cr] showed a high degree of correlation with
CD107a expression by FACS analyses. We next analyzed the
degranulation activity of murine CIK cells by evaluating their
capacity to mobilize CD107a to the cell membrane as a parameter
of tumor speciﬁc cytolysis. CIK cells showed a high cytolytic
capacity in 51Cr assays when directed against syngeneic and allo-
geneic tumor cell lines (A20, P3X63, EL4, Yac-1 and P815). CIK
cytotoxicity correlated with CD107a expression by FACS analyses.
Immunoﬂuorescence microscopy could conﬁrm the existence of
CD107a positive cytolytic granules in CIK cells from tumor cyto-
toxic assays. Using in vivo Bioluminescence Imaging (BLI) we
characterized the migration pattern of CIK cells derived from a
luciferase expressing transgenic mouse in tumor-bearing mice as
compared to healthy controls. Furthermore, Balb/c mice bearing a
sub-cutaneous A20 lymphoma, revealed tumor-speciﬁc homing of
CIK cells and reduction of the tumor size within 3 days after i.v.
injection. To identify tumor-speciﬁc CIK in vivo we are currently
combining imaging techniques with CD107a degranulation anal-
ysis. These data will help to elucidate the complex cellular inter-
action mounting a graft-versus-tumor response, which depends on
an effective combination of efﬁcient trafﬁcking, recognition and
elimination of the tumor cells.
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METHOTREXATE ALTERS HEMATOPOIETIC RECOVERY AND ENGRAFT-
MENT KINETICS WHEN ADDED TO CYCLOSPORINE FOR ACUTE GVHD
PROPHYLAXIS AFTER REDUCED-INTENSITY STEM CELL TRANSPLAN-
TATION
Dean, R.M.; Fowler, D.H.; Odom, J.; Castro, K.M.; Kasten-Sportes, C.;
Wilson, W.H.; Gress, R.E.; Bishop, M.R. Center for Cancer Research,
National Cancer Institute, Bethesda, MD.
Methotrexate (MTX) is a standard drug for graft-versus-host
disease (GVHD) prophylaxis, but its effects on hematopoietic re-
covery and donor engraftment in the setting of reduced-intensity
stem cell transplantation (RIST) are not well described. We com-
pared these parameters and acute GVHD in patients with hema-
tologic malignancies undergoing RIST on 2 consecutive clinical
trials using identical reduced-intensity conditioning (ﬂudarabine
and cyclophosphamide). Group 1 included 50 patients receiving
cyclosporine (CSA) alone for GVHD prophylaxis after RIST.
Group 2 included 24 patients receiving CSA MTX (5 mg/m2 on
days 1, 3, 6, 11) for GVHD prophylaxis. The groups were
similar with respect to host immune status before RIST, age, and
allograft dose of CD34 and CD3 cells. All patients in each group
received salvage therapy with etoposide, prednisone, vincristine,
cyclophosphamide, and doxorubicin plus ﬂudarabine (EPOCH-F)
prior to RIST. Fourteen patients in the CSA/MTX group also
received rituximab with EPOCH-F. Hematopoietic recovery was
delayed in the CSA/MTX group, with median neutrophil recovery
(500/L) and platelet recovery (100K/L) occurring 3 and 6.5
days later, respectively, than in the CSA group. Donor engraftment
was rapid and complete for most patients in each group (median
total mononuclear cell chimerism 100% at day 28 for both
groups), and no patient experienced graft rejection. However, full
donor chimerism (95%) was less common for CSA/MTX (75%
at day28, 71% at day100) than for CSA (90% at day28, 97%
at day 100). Adding MTX to CSA decreased the incidence and
severity of acute GVHD. Grade 2–4 acute GVHD occurred in
33/50 (66%) CSA patients, versus 9/24 (38%) CSA/MTX patients.
Grade 3–4 GVHD affected 17/50 (34%) CSA patients, including
6 with grade 4 GVHD and 8 with steroid-refractory disease. In
contrast, only 5/24 (21%) of CSA/MTX patients had grade 3
GVHD, while none had grade 4 or steroid-refractory GVHD. No
treatment-related deaths occurred in the CSA/MTX group, but 14
CSA patients died of treatment-related complications. Thus, the
addition of MTX to CSA markedly attenuates the GVH response
post RIST, slowing donor engraftment and delaying hematopoietic
recovery. These data illustrate the sensitivity of engraftment kinet-
ics to the intensity of GVHD prophylaxis following RIST. Further
studies should determine if CSA/MTX will be associated with an
increased risk of disease progression after RIST.
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GRADE 2–4 ACUTE GRAFT-VERSUS-HOST DISEASE AND EXTENSIVE
CHRONIC GRAFT VERSUS HOST DISEASE ARE ASSOCIATED WITH SIG-
NIFICANTLY DECREASED SURVIVAL FOLLOWING REDUCED INTENSITY
ALLOGENEIC STEM CELL TRANSPLANTATION
Chan, G.W.1; Klein, A.K.1; Sprague, K.A.1; Miller, K.B.2; Foss, F.M.1
1. Tufts-New England Medical Center, Boston, MA; 2. Beth Israel
Deaconess Medical Center, Boston, MA.
Grade 2–4 acute graft-versus-host-disease (aGVHD) and extensive
chronic GVHD (cGVHD) are associated with decreased overall sur-
vival (OS) following conventional allogeneic stem cell transplantation
but their impact on reduced intensity transplantation remains contro-
versial. We evaluated the impact of GVHD on survival in 112 high-
risk patients, median age 50 years (range 18–70), with AML (n29),
MDS (n19), CML (n9), CLL (n5), ALL (n3), HD (n10),
NHL (n16), MM (n9), MMM (n7), PNH (n2), or renal cell
carcinoma (n3), who underwent a reduced intensity preparative
regimen of extracorporeal photopheresis day 7, 6, pentostatin 8
mg/m2 by continuous intravenous infusion day 5 through 4, and
total body irradiation in three 200 cGy fractions day3,2, followed
by allogeneic bone marrow stem cell infusion from 6/6 HLAmatched
related (n70), 5/6 HLA matched related (n10), or matched unre-
lated (n32) donors. Thirty patients had prior autologous stem cell
transplantation and 5 patients had prior conventional allogeneic stem
cell transplantation. Full donor chimerism occurred in 89% of pa-
tients. Day 100 transplant related mortality (TRM) was 20%. The
disease relapse rate was 22%. Grade 2, 3 or 4 aGVHD occurred in
7%, 6%, and 6% of patients respectively. The one-year OS by
aGVHD grade was 70% for grade 0, 69% for grade 1, 29% for grade
2, 17% for grade 3, and 0% for grade 4. Grade 2–4 aGVHD was
associated with higher day 100 TRM (37% vs 14%: p0.03) and
decreased median OS (5 months vs “not reached”: p0.001). Median
OS was lower among patients with grade 2–4 aGVHD as compared
to patients with grade 0–1 aGVHD in matched related donor trans-
plants (5 months vs “not reached”: p0.002) and in mismatched
related or matched unrelated donor transplants (6 months vs 35
months: p0.0004). Patients with grade 2 or grade 3–4 aGVHD had
similar median OS (6 months vs 3 months: p0.24). Patients with
limited or no cGVHD had similar one-year OS (90% vs 79%) but
patients with extensive cGVHD had a signiﬁcantly worse one-year
OS (56% vs 82% p0.0007). In conclusion, high-risk patients who
undergo reduced intensity transplantation and develop grade 2–4
aGVHD or extensive cGVHD tolerate GVHD poorly, leading to
signiﬁcantly higher TRM and decreased overall survival. Patients with
grade 2 aGVHD or grade 3–4 aGVHD have similarly poor OS. To
improve survival, reduced intensity transplantation regimens that de-





SIGNIFICANCE OF ONE HUMAN LEUKOCYTE ANTIGEN MISMATCH ON
OUTCOME OF NON-MYELOABLATIVE ALLOGENEIC STEM CELL TRANS-
PLANTATION FROM RELATED DONORS USING THE MEXICAN SCHED-
ULE
Ruiz-Arguelles, G.J.1,2; Lopez-Martinez, B.2; Manzano, C.1; Gomez-
Rangel, J.D.1; Lobato-Mendizabal, E.1 1. Centro de Hematologia y
Medicina Interna, Puebla, Mexico; 2. Laboratorios Clinicos de Puebla,
Puebla, Mexico.
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Using the Mexican approach to conduct non ablative stem cell
transplantation (NST), we have prospectively done 58 allografts in
individuals with various malignant and non-malignant hematolog-
ical diseases using sibling donors, either HLA identical (6/6) or
compatible, with one mismatch (5/6). When comparing allografts
done from HLA identical (n 40) or compatible (n 18) siblings,
respectively, the overall median survival was found to be 33 versus
8 months (p 
.01), the 52-month survival was 47 versus 38% (p
.2), the prevalence of acute graft versus host-disease (GVHD) 57
versus 38%, that of chronic GVHD 25 versus 11% and the relapse
rate 45 versus 55%. The two patients who failed to engraft were
both 5/6 matches. Probably stemming from the low number of
patients, and despite a trend toward worse results in patients
allografted from HLA compatible (5/6) siblings, most differences
in outcome were not signiﬁcant. It seems that NST can be offered
to individuals with either an HLA identical or a compatible sibling
donor.
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SUCCESSFUL UNRELATED UMBILICAL CORD BLOOD TRANSPLANTA-
TION FOR SHWACHMAN-DIAMOND SYNDROME
Vibhakar, R.; Rumelhart, S.; Tatman, D.; Radhi, M.; Goldman, F.
University of Iowa Hospitals & Clinics, Iowa City, IA.
Shwachman-Diamond Syndrome (SDS) is an autosomal reces-
sive disorder characterized by pancreatic insufﬁciency and variable
degrees of neutropenia. Additional clinical features include short
stature, skeletal abnormalities and bone marrow dysfunction. SDS
patients are at increased risk of developing myelodysplasia, aplastic
anemia and leukemic transformation. The role and timing of allo-
geneic hematopoietic stem cell transplantation (HSCT) in SDS
remains controversial due to a poorly deﬁned predisposition to-
ward peri-transplant complications and overall poor survival. Here
we report three SDS patients (age 13 mo, 16 mo and 8 yr) with
severe aplasia successfully transplanted using 5/6 HLA matched
unrelated umbilical cord blood. All patients received a previously
described “cardiac sparing” conditioning regimen consisting of
Melphalan (180 mg/m2), Etoposide (1200 mg/m2), anti-thymocyte
globulin (90 mg/kg), and low dose total lymphoid irradiation (500
cGy) with graft versus host disease (GVHD) prophylaxis consisting
of cyclosporine and prednisone. Patients received grafts containing
6.7–9.1  105 CD34 cells/kg. Myeloid engraftment occurred
promptly with the ANC 500 cells/mm3 on day 15 	 5. Platelet
recovery (20k without transfusion) occurred on day 20, 30 and 140
days post transplant. All patients displayed 100% donor chimerism by
2 months post transplant. Patients were discharged between 25–60
days post transplant without severe complications, though all patients
displayed grade II or III acute GVHD, and one developed chronic
GVHD. The patients are alive 85, 390 and 850 days post transplant.
Factors that may be important in HSCT outcome for SDS include
transplantation at a relatively young age prior to malignant transfor-
mation, avoidance of cyclophosphamide in the preparative regimen,
and adequate GVHD prophylaxis. Importantly, these cases also sug-
gest that unrelated umbilical cord blood, in the absence of a matched
family member, should be considered as the preferred source of donor
stem cells in SDS patients undergoing HSCT.
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DONOR AGE AND DEGREE OF HLA MATCHING HAVE A MAJOR IMPACT
ON RESULTS OF THE UNRELATED HAEMATOPOIETIC CELL TRANS-
PLANTATION (UD-HCT) FOR CHRONIC MYELOID LEUKAEMIA (CML)
Carreras, E.1; Jimenez, M.1; Gomez-Garcia, V.2; de la Camara, R.2;
Martin, C.3; Martinez, F.3; Iriondo, A.4; Sanz, G.5; Canizo, C.6;
Cabrera, R.7; Sierra, J.8; Vallejo, C.9; Lopez, J.10 1. Hospital Clinic,
Barcelona, Spain; 2. Hospital de la Princesa, Madrid, Spain; 3. Hospital
Reina Soﬁa, Cordoba, Spain; 4. Hospital Marques de Valdecilla, San-
tander, Spain; 5. Hospital La Fe, Valencia, Spain; 6. Hospital Univer-
sitario, Salamanca, Spain; 7. Hospital Puerta de Hierro, Madrid, Spain;
8. Hospital de Sant Pau, Barcelona, Spain; 9. Hospital Universitario,
Murcia, Spain; 10. Hospital Ramon y Cajal, Madrid, Spain.
We analyzed consecutive adult patients with CML in ﬁrst
chronic phase that had received a blood or marrow UD-HCT
in Spain during last decade. Only donor-recipient pairs typed,
at least, at antigen level for HLA-A and B loci and at allele level
for DRB1 locus were included. Between November 1994 and
January 2003, 92 patients fulﬁlling these criteria underwent
UD-HCT in the ten centers participating in the study. These
centers performed 89% of the UD-HCT for CML in Spain during
this period. The median age of the patients was 32 years (range, 15
to 49). Seventy three pairs (79%) matched for DRB1	DQB1 loci
at allele level and for A, B 	 C loci at antigen or allele level and 19
pairs had one or more mismatch. The actuarial probability of
survival and disease free survival at 4 years for the whole group was
50% (95% CI: 39%-61%) and 46% (95% CI: 35%-57%), respec-
tively. Univariate analysis showed that factors associated with a
better survival were donor age less than 36 years (p 0.012),
matching for 8/8, 9/10 or 10/10 loci by high resolution techniques
(p0.003), and use of CsA since day 7 as GvHD prophylaxis
(p0.001). In multivariate analysis, only donor age (p0.003;
RR2.9 [95% CI: 1.4 - 6]) and donor-patient HLA-matching 8/8,
9/10 or 10/10 (p0.009; RR: 4.9 [95% CI: 1.5 - 16]) maintained
their signiﬁcance. The two-year probability of survival in the
subgroup of patients receiving a UD-HCT from a donor younger
than 36 years that matched for 8/8, 9/10 or 10/10 loci, was 91%
(95% CI: 74%-100%). Our results indicate that the outcome of
UD-HCT has notably improved and that this therapeutic ap-
proach should be considered in CML patients with young donors
matching at allele level for A, B, C, DRB1 and DQB1 or with a
single allelic mismatch.
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DONOR FACTORS INFLUENCING UNRELATED VOLUNTEER DONOR SE-
LECTION FOR HAEMATOPOIETIC STEM CELL TRANSPLANTATION
Little, A.-M.; Cleaver, S.; Maldonado Torres, H.; Marsh, S.G.E.;
Bronwen, S.; Madrigal, A. The Anthony Nolan Trust, London, United
Kingdom.
An important question that is faced by all unrelated donor reg-
istries is how to improve the provision of matching donors. In
order to address this question it is necessary to understand the
genetic diversity of the donor pool. Within the Anthony Nolan
Trust (ANT) donor database, 268,321 individuals have deﬁned
HLA-A, -B, -DRB1 phenotypes, of which 44% are distinct, and
71% of distinct phenotypes are unique. Analysis of the ANT
database has shown that new phenotypes continue to be added to
the register from North European donors. Thus recruitment from
all ethnicities will continue to add diversity to the register. In 2003
of the 314 donors provided for transplant by the ANT Register,
76% were male, with 60% of recipients being male. In 2003 46%
of donors added to the ANT register were male. Therefore there
is disparity between recruitment and usage of donors based on
gender. The use of mobilised peripheral blood (PB) stem cells as an
alternative form of donation has increased for unrelated donor
donations. In 2003 the majority of requests (65%) from transplant
centres were for PB. For these requests 58% of donors agreed to
give PB donations. Within the ANT patient/donor cohort an
increase in time to engraftment was observed for patients receiving
BM transplants (p0.002) and an increase in the time to onset of
cGVHD was also observed for BM recipients compared with PB
(p0.023). It is important for Registries to follow the use of PB
donations as this may inﬂuence donor recruitment in the future
with different medical criteria being necessary to assess the two
routes of donation. CMV status and donor age are linked factors
within the ANT donor population, with 77% of potential donors
aged 18–35 and 53% of potential donors aged 46–60 being CMV
negative. In 2003, 72% of the donating donors were CMV negative
(61% of patients were CMV negative). Studies of the ANT cohort
have shown signiﬁcant differences in survival of patients for the
following factors with the ﬁrst factor associated with increased
survival: patients under 40 versus over 40 (p0.029); donor under
30 versus over 30 (p0.024) and patients CMV negative versus
CMV positive (p0.014). In summary, to increase the efﬁciency of
unrelated donor registries it is necessary to have a clear under-
standing of the various factors that inﬂuence donor selection.
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